Clinical Trials Snapshot

Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL

Phase 2 study to evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia. This study is targeting patients with newly diagnosed B-ALL predicted to have an exceedingly poor outcome with conventional chemotherapy, in high-risk first relapse, or in second or greater relapse.

Phase 2 study to evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia. This study is targeting patients with newly diagnosed B-ALL predicted to have an exceedingly poor outcome with conventional chemotherapy, in high-risk first relapse, or in second or greater relapse.